- Vienna 2018
- Athens 2019
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
First Author: J.Sengupta INDIA
Co Author(s): S. Saha A. Khetan M. Fernandez A. Borthakur N. Gangopadhyay
Back to previous
To report the role of topical MitomycinC (MMC) 0.02% drops in the treatment of superior limbic keratoconjunctivitis (SLK).
Tertiary care eye hospital of eastern India
Sixty one patients with SLK refractory to medical treatment were treated with 0.02% topical MMC 3 times a day every alternate week for 3 cycles. Maintenance therapy was continued with preservative-free artificial tears, and a lubricant ointment. The patients were evaluated for symptomatic and clinical improvement after 2 weeks, 1 month, 3months, 6 months,12 months and in 21 patients for >24 months.Impression cytology was also performed in all eyes before and after treatment.
After 2 cycles of topical MMC treatment, symptoms of foreign-body sensation, irritation, and photophobia and signs of conjunctival hyperemia, tarsal papillary reaction, and filamentous keratopathy improved remarkably in all patients. The patients were comfortable with topical MMC. None of them suffered from systemic or serious local side effects. Post treatment conjunctival impression cytology demonstrated decrease in severity of squamous metaplasia, decrease in cells with snake chromatin and appearance of goblet cells. Number of patients with recurrences at 6 months,12 months and 24 months are 2,6 and7 respectively.
Topical MMC 0.02% can be effective in patients with SLK who do not respond to other treatment modalities. It can also be used in the long term to prevent recurrences.